Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Director | March 19, 2026 | March 23, 2026 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2026 | June 12, 2026 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,985.623 |
Reported balance
After 2026-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 2,158 · Balance 12,985.623 F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2: 85.693 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 13,873.623 |
Reported balance
After 2026-03-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 888 · Balance 13,873.623 F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.
F2: 85.693 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,894 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 12,894 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Lyell Immunopharma, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F2: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
| Common StockSEC Table I · non-derivative | Direct | 1,782 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,782 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F2: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:17 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 9,250 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001213029-26-000007 · form4-06122026_080623.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 6,111 | $0.00 Strike: $100.64 | $0.00 |
DisclosureSEC source: 0001213029-26-000005 · wk-form4_1781121922.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001213029-26-000005 · wk-form4_1781121922.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,894 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:36 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 888 | $111.75 | $99,234.00 |
DisclosureSEC source: 0001090872-26-000037 · form4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,873.623 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:36 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,158 | $111.75 | $241,156.50 |
DisclosureSEC source: 0001090872-26-000037 · form4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,985.623 F1 · price: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2 · balance_after: 85.693 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| January 12, 2026 Filed Mar 3, 2026 23:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,876 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007640 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,876 Underlying: Common Stock · 54,876 shares Expires 2036-01-12 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 22:00 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-25-022227 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 9,216 | $0.00 Strike: $70.07 | $0.00 |
DisclosureSEC source: 0001628280-25-031014 · wk-form4_1749760266.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-031014 · wk-form4_1749760266.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,252 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:45 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-25-013710 · form4-05192025_100517.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-05-14 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:46 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | PurchaseCommon Stock | 35,640 | $0.56 | $19,958.40 |
DisclosureSEC source: 0001415889-25-009604 · form4-04022025_070458.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,640 Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 13:56 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 812 | $121.18 | $98,398.16 |
DisclosureSEC source: 0001127602-25-009720 · form4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,741.93 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 13:56 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,819 | $121.18 | $220,426.42 |
DisclosureSEC source: 0001127602-25-009720 · form4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,929.93 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2 · balance_after: 55.473 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031290 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:07 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017147 · form4-06172024_080619.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 12,517 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0000879169-24-000094 · wk-form4_1718381735.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000094 · wk-form4_1718381735.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,734 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:19 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 750 | $147.48 | $110,610.00 |
DisclosureSEC source: 0001127602-24-010681 · form4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,055.457 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:19 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,678 | $147.48 | $247,471.44 |
DisclosureSEC source: 0001127602-24-010681 · form4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,305.457 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 42.181 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 20:22 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-048782 · doc4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-09-07 F1 · security: On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy. F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:29 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034838 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 20:41 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-038435 · doc4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,294 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0001209191-23-037793 · doc4.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037793 · doc4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,904 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:34 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 741 | $136.82 | $101,383.62 |
DisclosureSEC source: 0000899243-23-009212 · doc4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585.276 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:34 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,658 | $136.82 | $226,847.56 |
DisclosureSEC source: 0000899243-23-009212 · doc4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,844.276 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 20.375 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 20:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024468 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,124 | $0.00 Strike: $68.55 | $0.00 |
DisclosureSEC source: 0001209191-22-037793 · doc4.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock · 9,124 shares Expires 2032-06-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037793 · doc4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,399 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:13 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001209191-22-035853 · doc4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 21:05 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 797 | $136.82 | $109,045.54 |
DisclosureSEC source: 0001127602-22-010046 · form4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,165.901 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 21:05 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,785 | $136.82 | $244,223.70 |
DisclosureSEC source: 0001127602-22-010046 · form4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,368.901 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2 · balance_after: 0.901 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 19:10 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 179 | $162.16 | $29,026.64 |
DisclosureSEC source: 0001127602-21-029665 · form4.xml · nonDerivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583 F2 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 19:10 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 404 | $162.16 | $65,512.64 |
DisclosureSEC source: 0001127602-21-029665 · form4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 22:19 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,910 | $0.00 Strike: $69.26 | $0.00 |
DisclosureSEC source: 0001209191-21-058108 · doc4.xml · derivative · entry 2 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,910 Underlying: Common Stock · 5,910 shares Expires 2031-09-26 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 22:19 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058108 · doc4.xml · nonDerivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 23:20 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021501 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 23:19 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001140361-20-024925 · form4.xml · derivative · entry 1 BRAWLEY OTIS W · CIK 0001213029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-11-03 F1 · derivative.exercise_date: One-third (1/3) of the shares underlying the option shall vest upon each of the first, second and third anniversaries of the date of grant, such that the option will be fully vested on November 3, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.